A Phase I/II Trial of BAY 43-9006 [sorafenib] Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 31 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 30 Sep 2017.
- 04 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.
- 12 Jun 2013 Planned end date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.